Inovio announces appointment of steven egge as chief commercial officer

Mr. egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products inovio poised to become a commercial-stage company with plans to submit a biologics license application for ino-3107 in second half of 2024 under u.s. food and drug administration's accelerated approval pathway plymouth meeting, pa. , july 2, 2024 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced the appointment of steven egge as chief commercial officer.
INO Ratings Summary
INO Quant Ranking